# Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention

> **NCT06409299** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 150 (estimated)

## Conditions studied

- Tracheomalacia
- Bronchopulmonary Dysplasia (BPD)
- Vascular Ring
- Cystic Lung Disease
- Bronchiectasis
- Chronic Atelectasis

## Interventions

- **DRUG:** Azithromycin 40 MG/ML
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06409299
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409299, "Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06409299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*